Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 142

Sort by

Sort Order Select

Journal Articles

TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma

Blood (2025) 146 (21): 2544–2560.

https://doi.org/10.1182/blood.2024026919

Published: 2025

Includes: Supplemental data

Journal Articles

Association of CAR T cell kinetics with outcomes after standard of care brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma

Blood (2025) 146 (Supplement 1): 7092.

https://doi.org/10.1182/blood-2025-7092

Published: 2025

Journal Articles

Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk Mantle Cell Lymphoma: The window-3 clinical trial

Blood (2025) 146 (Supplement 1): 666.

https://doi.org/10.1182/blood-2025-666

Published: 2025

Journal Articles

primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 477.

https://doi.org/10.1182/blood-2025-477

Published: 2025

Journal Articles

Durable responses in the updated 2-year follow-up of patients from a single-center with Relapsed/Refractory peripheral T-cell lymphoma treated with golidocitinib

Eduardo Edelman Saul, Jessie Xu, Casey Bermack, Cathrine Paras, Jared Henderson, Kristofer Jennings, Bryan Valcarcel, Dr. Mohammad Abdul-Jaber Abdulla, Luis Fayad, Hun Lee, Preetesh Jain, Ranjit Nair, Michael Wang, Swami Iyer, Christopher Flowers, Luis Malpica

Blood (2025) 146 (Supplement 1): 5422.

https://doi.org/10.1182/blood-2025-5422

Published: 2025

Journal Articles

Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy

Blood (2025) 146 (Supplement 1): 1931.

https://doi.org/10.1182/blood-2025-1931

Published: 2025

Journal Articles

Phase II Trial of lenalidomide plus rituximab (R2) in previously untreated follicular lymphoma: 15-year follow up data from MDACC Trial

Dai Chihara, Paolo Strati, Preetesh Jain, Luis Fayad, Frederick Hagemeister, Maria Rodriguez, Richard Davis, Michael Wang, Sattva Neelapu, Christopher Flowers, Jason Westin

Blood (2025) 146 (Supplement 1): 5369.

https://doi.org/10.1182/blood-2025-5369

Published: 2025

Journal Articles

Germline variants and their role in the pathogenesis of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) in adult lymphoma patients

Blood (2025) 146 (Supplement 1): 806.

https://doi.org/10.1182/blood-2025-806

Published: 2025

Journal Articles

Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 5500.

https://doi.org/10.1182/blood-2025-5500

Published: 2025

Journal Articles

Trial in progress: Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma

Rahul Shah, Ruitao Lin, Amanda Mason, Lauren Johnson, Luis Malpica, Paolo Strati, Chijioke Nze, Preetesh Jain, Ayushi Chauhan, Swami Iyer, Gita Masand, Jennifer Ramos, Christopher Flowers, Jason Westin, Dai Chihara

Blood (2025) 146 (Supplement 1): 5525.

https://doi.org/10.1182/blood-2025-5525

Published: 2025

Journal Articles

A Phase II, single-center, single-arm study evaluating the safety and efficacy of golidocitinib in the management of newly diagnosed PTCL (GOLDEN Study)

Blood (2025) 146 (Supplement 1): 5434.

https://doi.org/10.1182/blood-2025-5434

Published: 2025

Journal Articles

Long-term clinical outcomes from the smart start trial: Rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 3691.

https://doi.org/10.1182/blood-2025-3691

Published: 2025

Journal Articles

Prehabilitation prior to CAR T-cell therapy in non-Hodgkin lymphoma: Baseline physical function and toxicity outcomes

Rahul Shah, Zhiping Luo, Rhodora Fontillas, Betty Holder, Nicholas Szewczyk, Amy Ayers, Uday Popat, Elizabeth Shpall, Paolo Strati, Chijioke Nze, Preetesh Jain, Michael Wang, Jason Westin, Sattva Neelapu, Amy Ng, Ki Shin, Sairah Ahmed, An Ngo-Huang, Dai Chihara

Blood (2025) 146 (Supplement 1): 2719.

https://doi.org/10.1182/blood-2025-2719

Published: 2025

Journal Articles

Mortality outcomes compared to the general population among long-term Hodgkin lymphoma survivors: A population-based analysis

Bryan Valcarcel, Michelle Hildebrandt, Maria Rodriguez, Sairah Ahmed, Hun Lee, Michael Wang, Preetesh Jain, Ranjit Nair, Swami Iyer, Christopher Flowers, Luis Malpica

Blood (2025) 146 (Supplement 1): 2716.

https://doi.org/10.1182/blood-2025-2716

Published: 2025

Journal Articles

Real-world treatment patterns and clinical outcomes in high-risk Mantle Cell Lymphoma: A retrospective analysis

Preetesh Jain, Anna Teschemaker, Essam Ibrahim, Taavy Miller, Danni Zhao, Ayush Kris, Ahmed Sawas, Debbie Adkins, Anouchka Chelles, Victoria Otero, Tycel Phillips

Blood (2025) 146 (Supplement 1): 4482.

https://doi.org/10.1182/blood-2025-4482

Published: 2025

Journal Articles

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Blood (2025) 145 (8): 823–839.

https://doi.org/10.1182/blood.2024025366

Published: 2025

Includes: Supplemental data

Journal Articles

High-risk MCL: recognition and treatment

Preetesh Jain, Michael Wang

Blood (2025) 145 (7): 683–695.

https://doi.org/10.1182/blood.2023022354

Published: 2025

Includes: Supplemental data

Journal Articles

T-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis Has Worse Survival When Compared to T-Cell Lymphoma: A Retrospective Analysis from a Single Tertiary Center

Blood (2024) 144 (Supplement 1): 6420.

https://doi.org/10.1182/blood-2024-211482

Published: 2024

Journal Articles

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Kunhwa Kim, Dai Chihara, Luis E. Fayad, Sattva S. Neelapu, Sairah Ahmed, Frederick Hagemeister, Chijioke Nze, Swaminathan P Iyer, Preetesh Jain, Michael Wang, Paolo Strati, Fateeha Furqan, Ayushi Chauhan, Michael R. Green, Christopher R. Flowers, Jason R. Westin

Blood (2024) 144 (Supplement 1): 4511.1.

https://doi.org/10.1182/blood-2024-205196

Published: 2024

Journal Articles

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3038.

https://doi.org/10.1182/blood-2024-206042

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma

Association of CAR T cell kinetics with outcomes after standard of care brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma

Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk Mantle Cell Lymphoma: The window-3 clinical trial

primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma

Durable responses in the updated 2-year follow-up of patients from a single-center with Relapsed/Refractory peripheral T-cell lymphoma treated with golidocitinib

Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy

Phase II Trial of lenalidomide plus rituximab (R2) in previously untreated follicular lymphoma: 15-year follow up data from MDACC Trial

Germline variants and their role in the pathogenesis of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) in adult lymphoma patients

Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma

Trial in progress: Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma

A Phase II, single-center, single-arm study evaluating the safety and efficacy of golidocitinib in the management of newly diagnosed PTCL (GOLDEN Study)

Long-term clinical outcomes from the smart start trial: Rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

Prehabilitation prior to CAR T-cell therapy in non-Hodgkin lymphoma: Baseline physical function and toxicity outcomes

Mortality outcomes compared to the general population among long-term Hodgkin lymphoma survivors: A population-based analysis

Real-world treatment patterns and clinical outcomes in high-risk Mantle Cell Lymphoma: A retrospective analysis

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

High-risk MCL: recognition and treatment

T-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis Has Worse Survival When Compared to T-Cell Lymphoma: A Retrospective Analysis from a Single Tertiary Center

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only